4//SEC Filing
Arkin Moshe 4
Accession 0000899243-21-018121
CIK 0001785530other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:31 PM ET
Size
17.6 KB
Accession
0000899243-21-018121
Insider Transaction Report
Form 4
Arkin Bio Ventures 2 L.P.
10% Owner
Transactions
- Purchase
Common Stock
2021-05-04$16.00/sh+400,000$6,400,000→ 2,046,634 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-05-04−10,714,284→ 0 total(indirect: See footnote)→ Common Stock (1,235,917 underlying) - Conversion
Common Stock
2021-05-04+1,235,917→ 1,235,917 total(indirect: See footnote) - Conversion
Common Stock
2021-05-04+410,717→ 1,646,634 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-05-04−3,560,551→ 0 total(indirect: See footnote)→ Common Stock (410,717 underlying)
Arkin Moshe
10% Owner
Transactions
- Conversion
Common Stock
2021-05-04+410,717→ 1,646,634 total(indirect: See footnote) - Conversion
Common Stock
2021-05-04+1,235,917→ 1,235,917 total(indirect: See footnote) - Purchase
Common Stock
2021-05-04$16.00/sh+400,000$6,400,000→ 2,046,634 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-05-04−10,714,284→ 0 total(indirect: See footnote)→ Common Stock (1,235,917 underlying) - Conversion
Series B Preferred Stock
2021-05-04−3,560,551→ 0 total(indirect: See footnote)→ Common Stock (410,717 underlying)
Arkin Bio Ventures GPGP Ltd.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2021-05-04−3,560,551→ 0 total(indirect: See footnote)→ Common Stock (410,717 underlying) - Purchase
Common Stock
2021-05-04$16.00/sh+400,000$6,400,000→ 2,046,634 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-05-04−10,714,284→ 0 total(indirect: See footnote)→ Common Stock (1,235,917 underlying) - Conversion
Common Stock
2021-05-04+1,235,917→ 1,235,917 total(indirect: See footnote) - Conversion
Common Stock
2021-05-04+410,717→ 1,646,634 total(indirect: See footnote)
Footnotes (3)
- [F1]On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund.
- [F3]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001321178
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 4:31 PM ET
- Size
- 17.6 KB